Inclisiran (inclisiran) — Uses, Dosage, Side Effects & Safety

Drug class: Small interfering RNA (siRNA) lipid-lowering agent

Overview

Inclisiran is a prescription medicine used to lower high levels of low-density lipoprotein cholesterol (LDL-C), often called 'bad cholesterol.' It is typically prescribed for adults with primary hypercholesterolemia (including familial and non-familial) or mixed dyslipidemia, especially when other cholesterol-lowering treatments and lifestyle changes are not enough. Inclisiran works by targeting a specific protein in the liver called PCSK9. By reducing the amount of this protein, inclisiran helps the liver remove more LDL cholesterol from the blood. This can help lower the risk of heart attack, stroke, and other cardiovascular problems. Key points for patients: Inclisiran is given as a subcutaneous injection by a healthcare professional, usually every six months after the initial doses. It is not a statin, but it can be used alongside statins or other cholesterol-lowering medicines. Regular cholesterol checks and follow-up appointments are important to monitor your progress.

Therapeutic uses

  • Primary hyperlipidemia
  • Mixed dyslipidemia
  • Atherosclerotic cardiovascular disease (ASCVD)

Common side effects

  • Injection site reactions
  • Arthralgia
  • Bronchitis
  • Diarrhea
  • Urinary tract infection
  • Hypersensitivity reactions

Frequently Asked Questions about Inclisiran

What is Leqvio?

Inclisiran — first-in-class small interfering RNA (siRNA) that lowers LDL cholesterol.

What is inclisiran?

Synthetic siRNA that blocks PCSK9 production in the liver.

How is Leqvio administered?

Subcutaneous injection (284 mg) by healthcare professional.

How often is Leqvio given?

Initial dose, 3 months later, then every 6 months.

How much does Leqvio lower cholesterol?

50–52% additional LDL-C reduction on top of maximal statin therapy.

What are the side effects of Leqvio?

Injection-site reactions (pain, redness, rash), joint pain, bronchitis; generally mild.

Is Leqvio better than Repatha or Praluent?

Similar LDL reduction; advantage is twice-yearly dosing vs every 2–4 weeks for PCSK9 monoclonal antibodies.

Does Leqvio cause muscle pain?

No increased myalgia compared to placebo.

Educational information only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.